Ardelyx (ARDX) Q4 2024 earnings summary

Executive summary

• Achieved strong commercial execution in 2024, with total revenue of $333.6M, up from $124.5M in 2023, driven by significant growth for both Ibsrela and Xphozah, supported by an expanded sales force and robust patient services programs.

• Ibsrela saw accelerated growth in Q4, driven by increased prescriber engagement and expanded targeting of non-GI and advanced practice providers.

• Xphozah's launch was highly successful, establishing it as a key therapy for dialysis patients, despite reimbursement challenges.

• Ended 2024 with $250.1M in cash, cash equivalents, and investments, supporting future growth and strategic investments.

• Reaffirmed combined peak sales guidance for Ibsrela and Xphozah at $1.75B.

Financial highlights

• Q4 2024 total revenues reached $116.1M, with full-year revenues at $333.6M, up from $124.5M in 2023.

• Ibsrela Q4 net product sales were $53.8M, nearly double Q4 2023, and up over 32% from Q3; full-year Ibsrela sales were $158.3M, up from $80.1M in 2023.

• Xphozah Q4 net product sales were $57.2M, up 11% from Q3; full-year Xphozah sales were $160.9M, compared to $2.5M in 2023.

• Net loss for 2024 was $39.1M ($0.17/share), improved from $66.1M ($0.30/share) in 2023; Q4 net income was $4.6M.

• R&D expenses rose to $52.3M (from $35.5M), and SG&A expenses increased to $258.7M (from $134.4M), reflecting sales team expansion and product launches.

Outlook and guidance

• Ibsrela 2025 net product sales guidance set at $240–$250M, with expectations to surpass $1B in annual sales prior to patent expiry.

• Xphozah expected to achieve $750M in annual net sales before patent expiry, but no 2025 revenue guidance provided due to payer mix changes.

• Gross-to-net deduction for Ibsrela expected to be 30% ±5%, less favorable in Q1 and improving by Q4; Xphozah gross-to-net expected to be less favorable in 2025 due to payer mix.

• SG&A expenses projected to increase by ~$10M per quarter in 2025 to support commercial growth and patient assistance programs.

• Confident in funding operations from current cash position.